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IN VITRO PERCUTANEOUS PENETRATION OF METHOTREXATE 
Abstract of Dissertation 
This research project was designed to investigate the ef-
fects of various physical and chemical parameters on percutan-
eous penetration of methotrexate. The potential of propylene 
glycol in water as a vehicle for topical delivery of metho-
trexate has been examined. A detailed examination of solubility, 
partition coefficient and pH parameters in the range of 2 to 6 
· ~pH un~~s has ~een conducted with the goal of correlating their 
effects on skin penetration of methotrexate. The importance of 
physiochemical parameters such as solubility and partition co~ 
efficient and their aid in the development of a suitable delivery 
system for topical application has been explained. In vitro 
percutaneous absorption of methotrexate was examined-across 
suitably characterized human cadaver skin samples. 
The results of this investigation suggested that the stratum 
corneum formed the main effective barrier for penetration of 
topically applied methotrexate. The analysis of the penetra-
tion data revealed relatively high lag times even at the most 
optimal pH, indicative of the low amounts of drug penetrating 
during the initial hours. These observations might explain 
the unsuccessful clinical results seen with topical methotrexate. 
At low pH values between 1 and 3, the protonation of the 
nitrogens possibly of the pteridine nucleus and also at the 10 
position was found to retard skin penetration. Between pH values 
3 and 5, the concentration of the unionized species present was 
optimal, contributing to penetration by passive diffusion. This 
was consistent with the improved rate of penetration and com~ 
paratively low values for lag times in this pH range. Relative-
ly low drug solubility in this pH range in the vehicle examined 
might account for lower rate and extent of penetration than those 
observed in the pH range 5 to 6. Beyond pH 5, the concentration 
of unionized drug was very low, yet the lag times, and rate and 
extent of p·enetration were the highest observed. Relatively high 
drug solubility and gradually increasing contribution of shunt 
pathways probably accounted for this. 
The results of this investigation emphasize the particular 
importance of in vitro skin penetration studies which should 
precede clinical trials. Based on the results of this investi-
gation, it is suggested that optimal conditions for topical de-
livery of methotrexate should include a vehicle system with a 
pH of about 4 capable of dissolving the drug to the extent of 
0.4% wfv or more while still retaining good partitioning charac-
teristics for the skin. 
DEDICATION 
To my Dad. 
ii 
ACKNOWLEDGEMENT 
I would like to express my sincere gratitude and special 
appreciation to Dr. Madhukar G. Chaubal and Dr. Ravindra C. 
Vasavada for their encouragement, guidance and construc-
tiy_e -~r~i;i_c_ism thJ:'011ghout the course of this study. 
Acknowledgments are due to Dr. Marvin H. Malone, Dr. 
Patrick R. Jones and Dr. Boyd J. Poulsen for their helpful 
discussions, invaluable suggestions and counsel, as well 
as their assistance as dissertation committee members. 
Grateful acknowledgment is also extended to Dr. Richard 
E. Jones~. Syntex Research, Palo Alto for supply~ng the human 
cadaver skin samples and to Dr. Stanley Penzotti, Lederle 
Labs. , New York for providiQ.g.samples of Methotrexate. 
The financial assistance awarded to this author has 
enabled this pursuit of knowledge. To Dean Ivan W. Rowland, 
Assistant Dean Carl C. Riedesel and Dean Louis C~ Martinelli 
of the School of Pharmacy for their recommendations and to 
Dean Reuben W. Smith III of the Graduate School, University 
of the Pacific, foi his generosity, this author extends his 
thankful appreciation. 
To Dr. Kishori M. Chaubal, Dr. and Mrs. Lohit Tutupalli, 
for their moral support, to Dr. Ashok V. Daftary for the good 
health and my fellow graduate students, Dr. See-Yan Lam, 
iii 
Ms. Terry Hair, Mr. Arshad R. Khan, Mr. Nitin V. Sheth and 
Dr. Scott Robertson, the author wishes to express his sincere 
gratitude. 
Special thanks to Carol Sarnoff for excellent typing 
of the manuscript. 
Finally, the author dedicates his past, present, and 
future works and accomplishments to Him. For ... per Ipsum, 
et cum Ipso, et in Ipso, est tibi Deo Patri omnipotenti, 
in unitate Spiritus Sancti, omnis honor et gloria. Per 
omnia saecula saeculorum. 
\, ,~ 
iv 
TABLE OF CONTENTS 
Page 
LIST OF TABLES. vii 
LIST OF.FIGURES . viii 
INTRODUCTION. . 1 
Current Status of Topical Methotrexate Therapy. 2 
Solubil~ty Characteristics and Percutaneous 
Penetration . • . . . . . . . 5 
pH of the Vehicle and pK of Drug 
a 
Scope of the Present Study .. 
THEORY .. . . .. . . 
Solubility of Drug in the Vehicle 
Partition Coefficient . 
Nature of the Vehicle 
Choice of Optimal Vehicle . . ~ 
pH of the Vehicle and pKa of Drug 
Limitation of In Vitro Study .. 













Determination of Purity of Methotrexate U.S.P.. 23 
Solubility Studies .. 24 
Partition Coefficient 25 
Results and Discussion .. 27 
~.v 
TABLE OF CONTENTS 
(continued) 
Purity of Methotr~xate U.S.P. 
Solubility Studies .. 
Partition Coefficient. 
Choice of Optimal Vehicle. 
EXPERIMENTAL II ... 
Determination of In Vitro Penetration Rate 
and Distribution-of Methotrexate . . . . 
Results and Discussion 
EXPERIMENTAL III . . 










Percutaneous Penetration . . . . 55 
Solubility Studies . 
Results and Discussion . 
Effect of pH on In Vitro Percutaneous 
Penetration. .-. . .. 
Results and Discussion 
Interpretation of Penetration Data 
CONCLUDING REMARKS . 
APPENDIX I . 
APPEND IX I I . . 
REFERENCES . 
vi 























LIST OF TABLES 
Retention Time and Area Percent of Peaks 
for High-Performance Liquid Chromatogram 
of Methotrexate U.S.P. in 85% 0.005 M/1 
Ammonium Acetate in Water (pH 5.0) and 
15% vjv Acetonitrile ......... . 
Solubility and pH of Methotrexate U.S.P. 
---:en-Propylene- Ciiycoi-water System. . . . 
Partition Coefficient of Methotrexate 
U.S.P. in Isopropyl Myristate/Propylene 
Glycol-Water System at 220 + 0.50 ... 
In Vitro Skin Penetration Data of Metho-
trexate. . . . . . . . . . . . . 
Relative Distribution of Methotrexate 14 
Days After Application . . . . . 
Solubility .and pH of Methotrexate U.S.P. 
in 50% vjv Propylene Glycol in Aqueous 
Mediun1. . . . . . . . . . . . . . . . 
Effect of pH on In Vitro Percutaneous 
Penetration of Methotrexate. Penetration 
Data : SET I ............ . 
Effect of pH on In Vitro Percutaneous 
Penetration of Methotrexate. Penetration 
Data : .SET I I . . . . . . . . . . . . 
Effect of pH on 'In Vitro Percutaneous 
Penetration of Methotrexate. Penetration 
Data : SET III ........... . 
Effect of pH on Relative Distribution of 
Methotrexate 14 Days After Application 
SET I . . . . . . . . . . . . . . . . 
Effect of pH on Relative Distribution of 
Methotrexate 14 Days After Application 
SET I I. . .. . . . . . . . . . . . . . 
Effect of pH on Relative Distribution of 
Methotrexate 14 Days After Application 
























LIST OF FIGURES 
Chemical structure of methotrexate .... 
Representative plot of solubility of drug 
against percent cosolvent in the vehicle. 
-
Representative plot of partition coefficient 
of drug against percent cosolvent in the 
vehicle. . . . . . . . . . . . . . . . 
Representative plot of solubility and par-
tition coefficient of drug against percent 
cosolvent in the vehicle . . . . . . . . . 
Representative HPLC standard plot of area 
under the curve against concentration for 
methotrexate U.S.P. dissolved in propylene 
glycol-water mixture. . . . . . . . . 
Chromatogram.of methotrexate in 85% vjv 
0.005 M/1 ammonium acetate in water (pH 5.0) 
and 15% vjv acetonitrile. . . . . .... 
Plot of solubility of methotrexate U.S.P. 
against percent propylene glycol in propylene 
glycol-water system . . . . . . . . . . . . . 
Semi-log plot of solubility of methotrexate 
U.S.P. against percent propylene glycol in 
propylene glycol-water system . . . . . . . . 
9. Plot of partition coefficient of methotrexate 
U.S.P. in isopropyl myristatejpropylene 










glycol. . . . . . . . . . . . . . . . . . . . 35 
10. ' Log-log plot of partition coefficient of 
methotrexate U.S.P. for isopropyl myristatej 
propylene glycol-water systems as a function 
of propylene glycol concentration in the 















LIST OF FIGURES 
(continued) 
Solubility-partition coefficient-percent 
propylene glycol profile for methotrexate 
U.S.P. in propylene glycol-water system. . . 
Diagramatic representation of the diffusion 
cell used in penetration studies. 
-
In vitro percutaneous penetration of me tho-
· -trexate Q versus t plot, SET I . . . . . 
In vitro percutaneous penetration of me tho-
trexate Q versus t plot, SET II. . . . . 
In vitro percutaneous penetration of me tho-
trexate Q versus t plot, SET III . . . . 
In vitro percutaneous penetration of me tho-
trexate Q versus t plot, SET IV. . . . . 
Plot of solubility of methotrexate u.s~P. 
against pH of saturated solution of the 
drug in 50% vjv propylene glycol-aqueous 




Semi-log plot of solubility of methotrexate 
U.S.P. against pH of saturated solution of 
the drug in 50% vjv propylene glycol-aqueous 
medium. . . . . . . . . . . . . . . . . 
Semi~log plot of molar concentration of 
hydrochloric acid against molar solubility 
of methotrexate U.S.P. in 50% vjv propylene 
glycol-hydrochloric acid mixtures . . . . . 
Plot of molar solubility of methotrexate 
U.S.P. against molar concentration of potas-
sium hydroxide in 50% vjv propylene glycol-
potassium hydroxide. in water mixtures . . . -
Effect of pH on in vitro percutaneous.pene-
tration of methotrexate : Q versus .t plot. 
SET I . . . . . . . . . . . . . . . . . . . 
Effect of pH on in vitro percutaneous pene-
tration of methotrexate Q versus t plot. 















LIST OF FIGURES 
· (co]ltinued) 
23. Effect of pH on in vitro percutaneous pene- / 
tration of methotrexate : Q versus ,t plot. 
Page 
SET I I I . . . . . . . . . . . . . . . . . . 67 
24. Semi-log plot of rate of penetration against 
pH for me·thotrexa te absorption from staura ted 
solutions of the drug in 50% vjv aqueous pro-
pylene glycol system. . . . . . . . . . . . 76 
_t")_t::, _____ O_YY'I~ __ ,_1:'\.lf"YY_'Y't.,_..f- ___ ..p ll""'oT?_._...,_..I""\ ._...,..,.._ "..p .......,oi""'\V\1"""\+~n+.;oi""'\Y\ 
~v • UClU.J.- .J.V!:, !J.L.V v V.J. a..V CJ. a. 0 v J..a, v v \.JJ. !JI:::Uv v.L a. V.LVU. 
against pH for methotrexate absorption from 
saturated solutions of the drug in 50% vjv 
aqueous propylene glycol in aqueous media . 77 
·x 
INTRODUCTION 
Methotrexate, an antineoplastic agent, is also effec-
tive for control of recalcitrant psoriasis. It has been 
shown to selectively inhibit DNA synthesis in psoriatic 
---eprdermal-cells,- thus decreasing the mitotic activity (1, 2) .--
Though there is no longer any doubt about the efficacy of 
methotrexate in dermatology (3), the risk of short- and 
long-term systemic side effects has precluded the use of 
this drug for most patients. Injection of intralesional 
methotrexate into psoriatic plaques shows a dose-related 
decrease in mitotic activity accompanied by production.of 
methotrexate 'damaged cells' beginning 2 hours after injec-
tion (4). These effects are similar to those found in 
psoriatic epidermis following systemie administration of 
methotrexate. The data suggest that methotrexate acts 
directly on the psoriatic plaques rather than systemically 
at a distant site. This finding along with the need to 
circumvent the toxic side effects of systemic administra-
tion of methotrexate on gastrointestinal tract, bone mar-
row, hair roots (5), and liver (6,7) has prompted a con-
tinuing search in the last two decades for safe topical de-
livery of methotrexate to the affected skin. 
1 
Current Status of Topical Methotrexate Therapy 
Clinical trials of topical methotrexate therapy have 
unfortunately been uniformly disappointing. 
2 
Condit (8) in 1961 reported that very small amounts 
of methotrexate, 0.5 mgjkg, inhibit conversion of folic 
acid to folinic acid in mice. In addition the author also 
showed that topically applied methotrexate is absorbed 
- t-hrough -psor-ia tTc -resrons. -Nurse ( 9) in 1963, failed to 
confirm the above findings following topical application 
of 0.5% methotrexate in a water-miscible ointment base 
on rabbit and human skin under occlusive and non-oc·clusive 
conditions. Nurse suggested that the body levels of folinic 
acid must be depleted by previous smalLparenteral doses 
of methotrexate beforeany local.action can be demonstrated. 
Fry and McMinn (10) in 1967 reported varying degrees of re-
mission of psoriasis following topical application of 0.2% 
methotrexate in an aqueous base. They proposed that the 
action of methotrexate appeared to be directly on the epi-
dermal cells. According to these authors the variability 
in response was probably due to the different levels of 
folic acid reductase in the psoriatic skin. In addition, 
the authors disagreed with Van Scott and Reinertson's 
theory (11) that methotrexate acts at a distant site from 
the skin to have an.effect on psoriasis. They also sug-
gested that the negative results of Nurse (9) were probably 
due to the instability of the formulation used by Nurse. 
However Comaish and Juhlin. (12) refuted the instability 
3 
theory while reporting no visible effect on psoriatic lesion 
when methotrexate was applied .topically within seven days 
after preparatiorr in aqueous cream, soft paraffin or 90% 
dimethylsulfoxide·in water- even at concentrations 40 
times greater than that use.d. by Fry. These authors. also 
concluded that rapid transit through the epidermis might 
have accounted for their inability to demonstrate epidermal 
lgtbe:l.ling _l::>y_ autoradiography following topical application 
of methotrexate. In a subsequent article, Comaish (13) 
proposed that methotrexate might act on skin cells in-
directly by its effect ott the liver. 
By. the 1970-1980 decade, researchers became increas-
ingly cognizant of the importance of pH and vehicle effects 
on percutaneous penetration. Furthermore, availability of 
radiolabeled methotrexate provided a more sensitive assay 
procedure by way of liquid .scintillation counting techniques. 
One of the first reports on percutaneous penetration 
of methotrexate was by Newbold and Stoughton (14) wherein 
the authors provided evidence for the in vitro penetration 
of methotrexate through hairless mouse skin and human skin. 
The concentrations studied. were 0.5% and 2.5% methotrexate 
under .controlled pH conditions. About the same time, Stewart 
and. co-workers ( 15) reported rapid in vivo absorption of 
topically appl.ied methotrexate through hairless mouse_ skin, 
but could not achieve comparable results through human skin. 
Certain dialkyl esters of methotrexate and 3' ,5'-dichloro-
methotrexate were synthesized and found to be inhibitors for 
4 
dihydrofolate reductase (16). Subsequent in vivo study 
by Weinstein and McCullough (17) demonstrated selective 
inhibition of psoriatic epidermal cells at lower concen-
trations of these drugs. In addition the ester derivatives 
were found to be more active than the parent compound, sug-
gesting that the increased lipid solubility potentiated 
their activity. While investigating this and other pos-
sibilities, McCullough and co-workers (18) could not achieve 
- - -
more than 2% penetration when tested in vehicles containing 
80% dimethylsulfoxide, 25% dimethylacetamide, 0.1% retinoic 
acid or 2.5% C-10 methylsulfoxide. More recently, Wallace 
and Barnett (19) have reported that parallel pathways 
exist for penetration· of topically applied methotrexate. 
According to these authors the fraction of the drug pene-
trating through the shunt pathway increases as vehicle pH 
and ionization increases. 
The surge in interest in the percutaneous penetration 
of methotrexate is evidenced by the increasing number of 
publications in recent years. However, the published re-
sults have often been contradictory and la~king in detailed 
examiriation of the various physico~hemical factors. They 
point to a need to investigate the effect of various physico-
chemical factors such as lipid solubility, pH, ionization, 
vehicle on the percutaneous penetration of methotrexate. 
An understanding of such factors is essential to achieve 
predictability in therapy and hopefully to provide a solu-
tion to the contradictory opinions and varied viewpoints. 
5 
Solubility Characteristics and Percutaneous Penetration 
The solubility characteristics of a substance greatly 
influence its ability to penetrate biological membranes. 
Assumi·ng passive diffusion as the primary mechanism for 
transepidermal absorption of methotrexate, concentration 
of the unionized species and its lipid solubility would be 
expected to play dominant roles in controlling the overall 
rate and _e~tent _ o_f abso_rption. The aqueous solubility of 
the drug would determine the concentration presented to 
the absorption site, while the partition coefficient would 
influence the rate of penetration across the absorption site. 
Since the solubility of methotrexate is a function of pH, 
comparison of pH-solubility profile with both pH-rate 
of penetration profile and solubility-rate of penetration 
profile could be very instructive. 
pH of the Vehicle and pK of Drug 
a 
One of the main parameters affected by pH of the 
vehicle is the polarity of the diffusing molecule. Absorp-
tion by passive mechanism is maximized when the concentra-
tion of non-polar molecules is greatest, thereby positively 
affecting the diffusion gradient of drug across the mem-
brane ( 20). The molecular structure of methotrexate pre-
sents a complicated situation for correlation of kinetic 
parameters with penetration rate. Methotrexate has five 
pK values, three of which 5.71, <-1.5, and 0.5 are associ-
a 
ated with the protonation of nitrogens at 1, 5, and 10 
6 
positions respectively (21) while the other two correspond 
to the ionization of the a. and y carboxylic groups (Figure 
1). Unfortunately, a review of the literature provides 
three different sets of pK values for the ionization of . a 
the a andy carboxylic groups, namely 3.36 and 4.70 (21), 
4.3 and 5.5 (22), and 4.8 and 5.5 (23). In view of the 
foregoing, the effects of pH on. the concentration of 
un_ionized me.tho_trexate have not been fully delineated. By -
using a saturated solution of. the drug in the vehicle at 
different pH, the thermodynamic activity of drug could be 
maintained at its maximum so that the correlation, if any, 
between flux and effective concentration of drug in the 
vehicle could be examined. 
Scope of the Present Study 
As pointed out earlier, the published results on 
percutaneous penetration of methotrexate have often been 
coritradictory and lacking in detailed examinatin of the 
various physicochemical factors. 
This research project was .designed to investigate 
the effects of various physical and chemical parameters 
on percutaneous penetration of methotrexate. The investi-
gation might help define a suitable vehicle system for 
the topical delivery of methotrexate. A detailed examina-
tion of solubility, partition coefficient and pH parameters 
in the range of 2 to 6 pH units was conducted with the goal 
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Figure 1. Chemical structure of methotrexate. 
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methotrexate. In vitro percutaneous absorption of metho-
trexate was also examined:across suitably characterized 
human cadaver skin samples. 
It is hoped that this investigation will contribute 
to a better understanding of the percutaneous penetration 
behavior of methotrexate leading to the development of an 
effective topical dosage form. 
THEORY 
The design of a delivery system for the topical 
application of a drug presents a challenging opportunity 
for research pharmacists and dermatologists. Increased 
~n~nv~~q_g_e ~pd _un_<ierstanding of the· physical-chemical 
parameters of drugs and adjuvants along with a trial-
and-error approach to.formulation has worked remarkably 
well in developing solutions to problems related to drug 
stability, physical·stabilityof formulation, irritation 
and sensitization properties, and aesthetic acceptability. 
In the past couple of decades, the focus of attention has 
shifted to correlating physicochemical parameters in an 
effort to optimize drug deli very from topical appliea tion. 
Although notable achievements have been made, the continuing 
effort has not. yet realized any blueprint· to insure optimal 
product (24). It is important to recognize that a variety 
of factors are involved in optimizing drug availability 
from topical dosage forms. At the same time, it should 
also be noted that a single topical product cannot be ideal, 
in terms of drug bioavailability, for every type of skin 
disease or for every patient. To quote J. J. Seelman (25), 
"My experiments have convinced me that there will probably 
never be such a thing as a universal ointment vehicle. On 
9 
10 
the contrary, I believe that the more the problem is 
studied the more it will be realized that vehicles should 
be individualized in accordance with the drugs used, the 
therapeutic aim'and special needs of the disorder to 
be treated." 
Some of the important·. factors which influence per-
cutaneous absorption are: 
_ (~) __ .So~l.lQ~l~ ty ()f j:he_ penetrant. in the vehicle, 
(b) Partition coefficient of the penetrant between 
the vehicle and stratum corneum, 
(c) Nature o~ the vehicle, 
(d) pH of the vehicle and pKa of the penetrant, and 
(e) Molecular characteristics of the drug. 
For a number of drugs, physical parameters such as 
solubility.and partition coefficient have been shown to 
correlate wel1 with the rate of percutaneous penetration. 
Solubility and. partition coefficient information in con-
junction with the effect of changes of pH.on the thermo-
dynamic activity of ionizable drugs have been utilized 
to develop predictive models for optimizing drug avail-
ability with limited success. Of course it should be borne 
in mind that when dealing with a nonhomogeneous complex 
membrane like human skin, deviations from such predicted 
models must be expected. A brief discussion of some of 
the parameters of relevance to the present investigation 
follows. 
11 
(a) Solubility of Drug in the Vehicle 
The solubility of drug in the vehicle represents the 
concentration which is p'resented at the absorption site. 
When high concentrations of the penetrant are present in 
the donorphase, positive or negative deviations from 
Fick's law may occur as a consequence of the membrane 
changes induced or because the partition coefficient be-
t-,1leen- --t-he- dono-!!- -phase -and skin· membrane is not constant 
over the entire concentration. range. 
For a drug with limited aqueous solubility, a vehicle 
system comprising water as primary solvent with a mutually 
miscible cosolvent may often be utilized. If the cosolvent 
chosen is a solubilizer for the drug, the solubility could 
then be varied by altering. the relative proportions of the 
primary solvent and cosolvent. Increased.concentrations 
of drug in solution in the vehicle can be achieved by 
increasing the proportion of the cosolvent in the mixture. 
A representative plot of solubility against percent co-
solvent in the mixture would then look as shown in Figure 2. 
Additionally, such data may also reveal whether the drug 
solubility has first-order dependence on the proportion 
of cosolvent present in each vehicle. 
(b) Partition coefficient 
Partition coefficient, defined by the equation, 
P = C /C s v 
20 40 60 80 
Percent cosolvent in the vehicle 
Figure 2. Representative plot of solubility of drug 




where C and C are the concentrations of the drug in the s v 
stratum corneum and vehicle respectively, can be regarded 
as an index of drug's relative affinity for the skin and 
the vehicle. Greater the value of P, the lower is the 
interaction between the. drug and the vehicle. Conversely, 
a low P value indicates strong affinity between the 
drug and the vehicle and reflects the tendency of the drug 
to remain in the vehicle. 
--------- --------- -----
Due to difficulties involved in determination of 
solubility of drug in the stratum corneum, partition co-
efficients are usually obtained for some arbitrarily 
selected two-phase system. The drug is dissolved. in the 
aqueous vehicle, while the oil phase simulates the stratum 
corneum. Though partition coefficients by this method 
cannot be exactly related to the rate of diffusion through 
the skin, good correlation has .been shown for a number of 
compounds; For vehicles comprising a primary solvent and 
cosolvent, with cosolvent being a ·Solubilizer for the drug, 
the partition coefficient-percent cosolvent profile (Figure 
3) may mirror the solubility-percent cosolvent profile. 
(c) Nature of the Vehicle 
Vehicles do significantly affe6t the penetration of 
substances through stratum corneum (24). The physical 
characteristics of the vehicle are a major consideration 
in .vehicle selection. Substances may be more rapidly 
14 
100 
Percent cosolvent in the vehicle 
Figure 3. Representative plot of partition coefficient 
of drug against percent cosolvent in the vehicle. 
15 
released from vehicles having a low affinity for the pene-
trant, ;i.e. vehicles with relatively low solvent power 
for incorporated compounds may induce more rapid penetra-
tion (26). In general, a compound must be·.at least partially 
soluble in its vehicle so that it can be readily released 
into the receptor phase (skin barrier). High solubility 
may result in preferential retention of the drug. in the 
__ vehicle. 
The physical properties of vehicles are also import- · 
-
ant in the degree of occlusion they produce leading to 
water retention in the stratum corneum layer. The effi-
ciency of various types of vehicles in aiding penetration 
can be reasonably explained.on the basis of their effect 
on hydration of the stratum corneum or how the.vehicle 
alters the act.i vi ty of water in the stratum corneum and 
influences the stratum corneum-vehicle partition coefficient. 
Greases and oils.are the most occlusive vehicles and induce 
the greatest hydration through sweat accumulation. at the 
skin-vehicle interface (27). This can be accentuated by 
covering with occlusive bandages or plastic. Emulsions 
of the water-in-oil type are less occlusive than greases. 
Substances in the vehicle, such as humectants, which have 
a high affinity for water, would act in proportion. to the 
relative humidity of the environment. If the latter is 
low, the humectant would tend to dehydrate the stratum 
corneum and decrease penetration. 
16 
Some vehicles have pronounced.effect whenapplied to 
the skin surface. Certain nonaqueous bases promote pene-
tration by producing structural change or chemical damage 
in the barrier layer (28). Dimethylsulfoxide, dimethyl-
acetamide,.and dimethylformamide are examples of these. 
Low molecular weight volatile solvents such as 
ether, methanol, ethanol and acetone may enhance drug 
_ p_e1let:rat_ipn_. Subst_antial lipid extraction. from stratum 
corneum cells, which leaves.a more porous barrier, may be 
the likely explanation for this effect. 
Choice of Optimal Vehicle 
Diffusion of drug from the vehicle into the skin 
surface and subsequent penetration of drug through the 
stratum corneum.are functions of partition coefficient 
of drug between the stratum corneum and. vehicle and also 
of the rel-tive solubility of the drug in the vehicle 
(29.30). This concept of correlation of physical param-
eters such as solubility and partition coefficient with 
the rate of percutaneous. penetration for several compounds 
can be utilized judiciously to predict the choice of 
optimal vehicle for· subsequent in vitro penetration 
studies. 
For a vehicle comprising a primary solvent and co-
solvent, a representative plot as shown (Figure 4) of 
solubility and partition coefficient against percent co-
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Figure 4. Representative plot of solubility and partition 




























evident from the plot, that for percentages of cosolvent 
to the left of the crossover point, even though the par-
titioning of the drug is high, the concentration that 
could be presented to the absorption site is relatively 
low. On the other hand, for vehicle compositions with per-
cent cosolvent greater than that at the crossover point, 
even though the concentration is high, the partitioning 
yalJ.lS} _is _too __ low _so_ that the drug has a greater tendency 
to remain in the vehicle. Thus, at the crossover point 
an optim solubility and partition coefficient exists and 
an optimal vehicle composition is suggested. 
This m~thod of selecting a vehicle,is arbitrary and 
suffers from one limitation. As· can be visualized from 
the plot, an· alteration in the dimension of axis on either 
the solubility scale or the partition coefficient scale 
would shift the crossover point correspondingly·. But 
if one chooses to plot the maximum value of solubility 
on level with the maximum value of partition coefficient, 
then a symmetry exists wherein the curves mirror each 
other. The crossove~ point 6ould then serve as an indica-
tor of optimal vehicle composition. 
(d) pH of the Vehicle and pKa of Drug 
The selection of one particular vehicle composition 
based on the results of solubility and partition coefficient 
parameters provides a good basis for investigation of the 
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effect of pH on the rate of percutaneous penetration. 
Assuming that passive mechanism is operative for transport 
of drugs through biological membranes, for ionizable drugs 
the matter of interest would be the concentration of the 
unionized species which is presented to. the absorption 
site rather· than the total concentration of the drug it-
self. Depending .on the pK value of the drug, the pH of a 
the vehicle would determine the degree of ionization. 
Thermodynamic activity of a drug is the product of 
its-concentration and activity coefficient in the vehicle. 
Rapid release of the drug is dependent on its high thermo-
dynamic activity in the vehicle, as the direction of flow 
is always from the higher to lower thermodynamic potential. 
For specific concentrations of certain substances, it has 
been shown that thermodynamic activities may vary as much 
as 1000-fold from one vehicle to another (26). To aid in 
comparison of the results of in vitro percutaneous pene-
tration studies .at different pH,. the·thermodyanmic activity 
in each case can. be maintained at maximum value by use.of 
a. saturated solution of .the drug in vehicle. 
In vitro percutaneous penetration studies at. various 
pH values may reveal whether the flux has correlation to 
the total concentration presented· 6r.to the concentration 
of the unionized species or both. 
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Limitations of In Vitro Study 
Reviewing studies on in vitro percutaneous absorption, 
one should always bear in mind the limitations of the experi-
mental technique involved: 
(a) The in vitro skin technique may not reflect the 
role of the skin in vivo; 
(b) Predictions and conclusions are based on results 
of measurement for the steady-state rate with 
obvious difficulties for analyzing low concentra-
tions during the initial few minutes; 
(c) Normally, records for the sources of .skin used 
are unavailable which makes it difficult to ex-
plain the variability in observed results; 
(d) Information regarding age of the donor may not 
be available and age is an important criterion; 
and 
(e) _Skin from different sites of the body have dif-
ferent diffusional. characteristics. 
These limitations, while expressing the need for 
improvement in methodology, reflect the danger involved 
in comparing the work of various investigators. Improved 
in vitro techniques have been tried with a measure of 
success in correlating the various physical and chemical 
properties to the rate of percutaneous penetration. The 
main advantage of the in vitro technique is that it per-
mits absolute control of the environment allowing the 
21 
demonstration of the importance·of individual parameters 
towards percutaneous penetration of a given substance. 
Carefully conducted in vitro studies provide valuable 
information paving.the way for in vivo experiments and 
further development of effective topical dosage forms . 
.. 
EXPERIMENTAL I 
The protocol for the experimental study was based on 
the theoretical aspects discussed in the preceding chap-
ter. A preliminary investigation of the purity of metho-
~r~x~te ~ample was conducted. Solubility of the drug in 
a series of propylene glycol-water mixtures was then deter-
mined. The partition coefficient of methotrexate in the 
two-phase isopropyl myristatejpropylene glycol-water sys-
tem was also examined. Based on the results of s9lubility 
and partition coefficient determinations, an optimum com-
position of propylene glycol in water was chosen for further 
investigation. The in vitro skin penetration profile of 
methotrexate from this optimum·vehicle was studied. The 
results of this study were expected to provide greater 
insight into the penetration behavior of methotrexate from 
a propylene glycol-water system, and also establish a 
basis for subsequent investigation of the effect of pH 
on the in vitro penetration of methotrexate. 
Assay Method 
Analysis of samples for methotrexate was carried out 
by high-performance liquid chromatography by the method 
of Tong, Rosenberg, and Ludlum (31). The chromatograph 
22 
23 
was equipped with a 6000-psi pump1 , a variable wavelength 
detector2 and a loop injector. 3 A 30-cm long, 3.9 mm inner 
diameter stainless steel column4 was used. Accurate de-
termination of area under the curve was accomplished by 
use of an automated integrator system. 5 Injection volume 
was maintained constant with the aid of a gas-tight 800 
series microliter syringe6 which eliminated the need for 
use of a standard. The eluent was 85% 0.005 M/1 ammonium 
acetate7 in water (pH 5.0) and 15% v/v acetonitrile. 8 
The absorbance was recorded at 307 nm. The detector was 
set at 0.1 aufs and sensitivity at 0.02. 
Determination of Purity of Methotrexate U.S.P. 
Methotrexate U.S.P. 9 had 7.3% moisture (Karl Fischer). 
For purity determination, a small amount of methotrexate 
U.S.P. sample was dissolved in the solvent mixture used 
1waters 6000-A pump, Waters Associates, Milford MA. 
2Model 450, Variable Wavelength Detector, Water 
Associates, Milford MA. 
3u6K Injector, Waters Associates, Milford MA. 
4 
~-Bondapak, Waters Associates, Milford MA. 
5Data Module,Waters Associates, Milfo~d MA. 
6Hamilton Co., Reno NV. 
7HPLC grade, J.T. Baker Chemical Co., Phillipsburg 
8HPLC grade, J.T. Baker Chemical Co., Phillipsburg 





for elution. After dissolution, the solution was filtered 
through a 0.22~ filter. 10 Twenty ~1 of the sample was 
then injected on to the column. The column flow rate 
was set at 0.4 mljmin. ·The purity of the sample was cal-
culated as the ratio of area under the curve for the peak 
corresponding to methotrexate to the total area under the 
curve for all the different peaks observed. The methotrex-




The sdlubility of methotrexate U.S.P. in a series of 
propylene glycol-water mixtures varying from 20% propylene 
12 glycol in water to 80% propylene glycol in water was 
o o· determined at room temperature (22 + 0.5 ). An excess 
of methotrexate .was added to 25.0 ml of propylene glycol-
water mixtures in 50-ml amber-colored Erlenmeyer flasks 
with ground-glass stopper. A teflon-coated magnetic bar 
was placed in each of the flasks prior.to flushing with 
nitrogen and capping them tightly. The flasks were then 
kept stirred on magnetic stirrers for a period.of six 
days. Each determination was conducted.in triplicate in 
a constant temperature room. 
10swinnex-25, Millipore Filter Corp., Bedford MA. 
11u.s.P. Conveniion Inc., Rockville MD. 
12J.T. Baker Chemical Co., Phillipsburg NJ. 
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Prior to sampl.ing, the stirring was stopped and the 
excess drug was allowed to settle. An aliquot was then 
filtered using a filter with 0.22~ filter paper. The 
first 5 ml of the filtrate was rejected in each case to 
avoid any discrepancy in the determination of solubility 
values due to possible adsorption of drug to the filter 
paper. 
The cgncentration of methotrexate in the propylene 
glycol-water system was determined by high~performance 
liquid chromatography as discussed under assay method. 
Appropriate dilutions of the saturated solution of drug 
in the eluent were made prior to injection on to the 
column. A standard plot (Figure 5) of area under the 
curve against concentration for known amounts of the 
drug was determined. 
Partition Coefficient 
Preliminary experiments had shown that methotrexate 
reached equilibrium distribution in the two-phase isopropyl 
myristate13;propylene glycol-water.system in four days. 
Therefore, 3 ml of a saturated solution of methotrexate 
in the various propylene glycol-water mixtures was agitated 
for four days with 3 ml of the respective propylene glycol-
water saturated-isopropyl myristate in amber bottles. 
Blank flasks with 3 ml of saturated solution of methotrexate 
13Ruger Chemical Co. Inc., Irvington NJ. 
Ill 
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Figure 5. Representative HPLC standard plot of area under the curve 
against concentration for methotrexate U.S.P. dissolved in 
propylene glycol-water mixture. tv m 
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in the various propylene glycol-water mixtures and no 
isopropyl myristate were also shaken alongside. The par-
e titioning study was conducted at room temperature (22 + 
0.5°) in a constant temperature room. After equilibra-
tion, the aqueous phase and oil phase were separated by 
centrifugation. The aqueous phase, after appropriate dilu-
tions, was analyzed for methotrexate content. The 6on-
centration in the isopropyl myristate phase was deduced 
as the difference between the initial and final concen-
trations of drug in the propylene glycol-water phase. 
Partition coefficients were calculated as the ratio of 
isopropyl myristate to propylene glycol-water concentra-
tion of methotrexate. 
Results and Discussion 
Purity of Methotrexate U.S.P. 
Chromatograms (Figure 6) of a solution of methotrexate 
in the mixed solvent 85% vjv, 0.005 M/1 ammonium acetate 
in water (pH 5.0) and 15% vjv acetonitrile showed six peaks. 
Peak IV was identified as that of methotrexate by method of 
spiking with an authentic sample. The retention time and 
area percent of these six peaks for four different injec-
tions of the sample is shown in Table I. The purity of 












Figure 6. Chromatogram of methotrexate in 85% vjv 0.005 M/L 
ammonium acetate in water (pH 5.0) and,l5% vjv 
acetonitrile. 
TABLE I 
Retention Time and Area Percent of Peaks for High .... Performance Liquid ChroJnatogram of· Me tho:.. 
trexate U.S .P. in 85% v/v 0. 005,M/LAmmonium,Acetate,in.,Wate-L.(pH.S .. O) ,ana,15% v/v,Acetonitri1e 
Injection 11 Peak.I. Peak .. ti ."Peak .III. ."MTX Peak .... Peak.,~ .Peak."VI 
-
Q) 
1 8.80 9.60 10.13 12.10 16.53 21.23 s 
•r-l 
E-1 








4 8.41 9.25 9.75 11.50 15.62 19.75 ~ 
Mean Retention Time 8.49 9.35 9.84 11.64 15.82 20.10 
+J 
1 0.73 0.12 0.10 95.17 1.50 2.36 
r:: 
Q) 








4 0.73 0.15 0.09 . 95.54 1.23 2.23 <tl 





The solubility of methotrexate U.S.P. in 20%, 40%, 50%, 
60%, and 80% propylene glycol in water at 22° + 0.5° is 
shown in Table II, Figure 7. In addition the pH of the 
saturated solution of methotrexate in these vehicles is 
also listed. For determination of pH, a glass electrode 
with a Ag/AgCl internal reference electrode was used. 
Since a propylene glycol-water mixture is not· purely aque-
ous, the pH is referred to as the apparent pH. As can be 
seen, the solubility increases with increasing concentra-
tion of propylene glycol. The attainment of equilibrium 
solubility in 3 days was confirmed by the fact that there 
was no difference in solubility values between the samples 
analyzed at the end ~f 3 and 6 days. 
A semi-log plot of solubility against percent pro-
pylene glycol (Figure.8) showed a linear relationship. 
From the plot, solubility of methotrexate U.S.P. was found 
· to be related to percentage of piopylene glycol in the 
vehicle by the equation, 
ln S(mgjml) = 0.0362 (% propylene glycol) - 2.4852 
Partition Coefficient 
The partition coefficient values of methotrexate in 
tha two-phase isopropyl myristatejpropylene glycol-water 
system for 20%, 40%, 50%, 60%, and 80% propylene glycol 
in water are shown in Table III, Figure 9. As the percentage 
TABLE II 
Solubility and pH of Methotrexate U.S.P. in 
Propylene Glycol-Water System 
Solubilityb a 
ProE~lene Gl~col 22° + 0.5° 
% . mg/ml 
.. -20 0.1752 + 0.0048 
40 0.3052 + 0.0115 
50 0.5936 + 0.0308 
60 0.7444 + 0.0202 
80 1.4567 + 0.0363 








bAll solubility values are expressed as mean.+ standard devia-
tion of three determinations. 
cCorning Model.l25 pH meter with glass electrode and Ag/AgCl 
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Percent propylene glycol 
Figure 7. Plot of solubility of methotrexate U.S.P. against 
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Percent propylene glycol 
Figure 8. Semi-log plot of solubility of methotrexate 
U.S.P. against percent propylene glycol in 




Partition Coefficient of Methotrexate in Isopropyl Myristate/Propylene 
Glycol-Water System at 220 + 0.5° 
Number of 
Propylene Glycol a Partition Coefficient Determinations 
% k + 1 S.D. N 
n---- - r 
20 0.0454 + 0.0067 4 
40 0.0255 + 0.0096 4 
50 0.0203 + 0.0037 2 
60 0.0170 + 0.0025 2 
80 0.014.0 + 0.0005 3 
a -
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Percent propylene glycol 
Figure 9. Plot of partition coefficient of methotrexate 
U.S.P. in isopropyl myristatejpropylene glycol-· 
water system against percent propylene glycol. 
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of propylene glycol in the vehicle was increased, the par-
tition coefficient was found to decrease. This shows the 
increasing tendency of the drug molecules to remain in the 
vehicle with increasing fraction.of propylene glycol in 
the vehicle. 
A log-log plot of partition coefficient against 
percent propylene glycol in vehicle (Figure 10) showed a 
linea~ relationship. 
ficient. was found to be related to the percentage of pro-
pylene glycol in the vehilce by the equation, 
ln (kp) = -0.8651 ln(% propylene glycol) - 0.5002 
Choice of Optimal Vehicle 
For investigation. of in vitro percutaneous penetration 
of methotrexate a vehicle composition of 50% propylene 
glycol in water was chosen. 
Consideration of the advantages of presenting a rea-
sonably high concentration of drug in the donor ~ehicle 
necessitated use of a higher proportion of propylene glycol 
in the vehicle. This alongwith the opposing fact that higher 
proportions of propylene glycol might cause the barrier to 
become less permeable (29).made the choice of 50% propylene 
glycol in water more practicable. 
Additionally, the system appeared to provide a good 
balance between aqueous and.non-aqueous phases. The results 
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Figure 10. Log-log plot of partition coefficient of 
methotrexate U.S.P. for isopropyl myristate/ 
propylene glycol-water systems as a function 
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Figure 11. Solubility-partition coefficient-percent 
propylene glycol profile for methotrexate 























of the solubility-partition coefficient-percent propylene 
glycol profile (Figure 11) provides additional support 
to the selected vehicle composition. 
EXPERIMENTAL II 
Laboratory measurements of steady-state penetration 
rates and the experimental determination of the physical 
parameters affecting penetration rates provide valuable 
bench marks against which less well-controlled in vivo 
topical bioavailability studies can be compared. 
All penetration studies were conducted using excised 
human skin since most animal skin models may not satis-
factorily mimic human skin. The results of comparative 
evaluations of formulation effects on percutaneous absorp-
tion utilizing in vitro animal skin models may not be in 
agreement with those based upon human skin samples as was 
demonstrated by Chowham et al. (33). 
Determination of In Vitro Penetration 
Rate and Distribution of Methotrexate 
Preparation of Skin. All of the penetration experi-
ments reported here utilize human abdominal skin obtained 
at autopsy. Immediately following incision, the skin was 
placed in a plastic bag and stored in a freezer for periods 
up to but not exceeding three months. This method of 
storage has been reported not to damage the skin (34). 
Before the experiment, the skin was allowed to thaw gradu-




placed on a smooth dissection board with the· epidermal sur-
face flat in contact with the board. All subcutaneous fat 
was completely removed by a scalpel. From each specimen 
(the skin of a single donor), 6 to 8 pieces of suitable 
sizes were cut. 
Skin Cell.. Each piece of skin.wa:s mounted. in a special 
glass cell as illustrated. in Figure 12. The skin cell con-:' 
sisted of a lower glass chamber with a sampling port. A 
Teflon-coated magnetic bar placed at the bottom of the cell 
provided efficient mixing. The lower chamber was enclosed 
by a water jacket which·allowed circulation-of water at the 
selected temperature. The skin was placed in position 
on an 0-ring betweeri two ball joints of the top and.bot-
tom chambers, using a pinch type,-ground-joint clamp. 
2 The diffusion area was 2.01 em . The epidermal side of 
the skin was covered with Saran Wrap to provide occlusion~ 
Normal saline14 was pipetted into the skin cell bathing 
the dermal side. The sampling port was closed by a rub-
ber closure and any .. air bubbles on the dermal side were 
carefully removed by slightly tilting the cell. Each cell 
was mounted on a magnetic stirrer. The temperature of the 
fluid in the lower chamber was maintained at 37° + 0.5° 
by circulating water from a constant temperature water 
CA. 
14Abbott Laboratories, North Carolina IL. 





Figure 12. Diagramatic representation of the diffusion 





circulator15 through the jacket of each cell. This helped 
to simulate in vivo conditions. 
After mounting, ,each piece of skin was allowed to 
stand for 4 hours before beginning the experiment. This 
allowed adequate time for equilibration with respect to 
the temperature and relative humidity of the environment. 
During the actual run, each cell was covered and. the 
experiment carried out under minimum exposure.to light 
--- ---- -
in order to·minimtze photodecompositionof methotrexate. 
A saturated soluiion of methotrexate U.S.P. in 50% 
propylene glycol-water was used as the donor phase. One 
ml of this·solution was pipetted.onto the epidermal side 
of the skin aud the skin cell was covered with Saran wrap 
which provided good occulusion. 
All experiments were carried out for a period of 
· 14 days.. No samples were withdrawn during the first 80 
to 96 hours. ·Thereafter, at selected time intervals, pre-
ferrably once a day, the receptor solution from the bottom 
chamber was completely removed through the sampling port 
using a disposable syringe with its needle attached to a 
thin flexible plastic tubing. This allowed for a quick 
and complete removal of the receptor solution and refilling 
with fresh normal saline solution. The receptor samples 
15Haake-Model-FE, VWR Scientific Inc., San Francisco 
CA. 
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withdrawn were stored in the refriger~tor until the end of 
the experiment. The samples were then assayed·for metho-
trexate by high-performance liquid chromatographyfollow-
ing appropriate dilutions with normal saline. 
At the termination of. a penetration experiment, the 
remaining solution on the donor side was removed~ The 
epidermal surface was then washed of the remaining applied 
dose with three 1-ml portions of 50% propylene ~lycol in 
water. The washings were added to the original solution 
and t·he volume made up to 5 ml. This was then assayed 
for methotrexate after appropriate dilutions. 
The skin was then removed from the cell and the cir-
cular portion of the skin in contact with the bathing 
fluid was cut out using surgica'l scissors. The epidermis 
and dermis were easily separated by means of a forceps 
and collected separately in ·two amber colored Erlenmeyer 
flasks. To the epidermal portioh, 7.5 ml of .50% propylene 
glycol in water was added. The dermal portion was cut into 
very small pieces and 15 ml of 50% propylene glycol in 
water was added~ The contents of both flasks were then 
stirred for a period of 48 hours. At the completion of 
this time interval~ the solutions were assayed for metho-
trexate following appropriate dilutions. 
All samples were filtered through a disposable 0.22 l.1 
filter16 prior to dilution (if necessary) and injected on 
16 . Gelman Sciences, Inc., Ann Arbor MI. 
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to the column. Analyzing samples from in vitro skin pene-
tration experiments, it was necessary to modify the elution 
solvent mixture in order to overcome interference from 
peaks due to impurities from skin samples .. The polarity 
of the solvent was increased by using a mixture of 90% 
vfv 0.005 M/1 ammonium acetate in water (pH 5.0) and 10% 
vfv acetonitrile. This facilitated faster elution of the 
poJ_ar impurities. In order to decrease .the retention time 
of methotrexate peak, the flow rate was increased to 0.9 
mlfmin.· New standard curves were determined at the beginning 
of each analysis and checked after the completion of analysis. 
Knowing the areas under the curve for injection of different 
samples, the unknown concentrations were read from the. 
standard curve. 
Results and Discussion 
The penetration data for saturated solution of 
methotrexate in 50% propylene glycol in water were analyzed 
by plotting Q (amount penetrated per unit area) against 
time. Based upon this plot, a regression analysis of the 
steady-state region of the penetration curve was carried 
out using the regression program ona TI~55 calculator. 
The regression line was extrapolated to time axis to 
establish the lag times as shown by the dotted lines in 
Figures 13, 14, 15, and 16. The penetration data obtained. 























Figure 13. In vitro percutaneous penetration of methotrexate: Q versus t plot. 
SET I. 
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Figure 14. In vitro percutaneous penetration of methotrexate: Q versus t plot, 
SET Ii. 


















SET # III 
Run 4 
Figure 15. In vitro percutaneous penetration of methotrexate: Q versus t plot, 
SET III. 
















SET # IV 
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Figure 16. In vitro percutaneous penetration of methotrexate: Q versus t plot, 
SET IV. 




In Vitro Skin Penetration Data of Methotrexate, 
a 
Set 









Jlg/ml ]Jg em hr 
I 1 627.1 0.1992 190 0.984 
II 2 566.5 0.1272 158 0.999 
3 566.5 0.1122 176 0.998 
III 4 566.6 0.2190 187 0.998 
5 566.5 0.1015 223 0.990 
IV 6 627.1 o. 3692 0.999 
7 627.1 0.3663 80 0.999 
aSet numbers refer to skin specimens from different donors. 
bRuns 2 and 3, 4 and 5, and 6 and 7 are duplicate runs. 
cAll steady-state values were computed from the regression line drawn fron1 the data for 
each run by using a TI-55 calculator. 
dReported r values are for steady-state region of the penetration data. 




distribution of methotrexate at the end of 14 days is shown 
in Table V. 
From the results it is quite evident that methotrexate 
is absorbed to a widely variable extent by different ex-
cised human skin specimens .. Even pieces of skin immedi-
ately adjoining one another may show considerable varia-
tion in the rate and extent of absorption. The percentage 
of the applied dose recovered from the dermis was nearly 
the same as that from the stratum corneum. Results are 
reported only from those experiments where the stratum 
corneum appeared grossly intact at the end of 14 days. 
Experiments in which the stratum corneum was damaged dur-
ing the actual run, did not show much resistance to the 
passage of methotrexate. The concentration of the drug 
in the initial sample for such experiments was about 5 
to 10 times that for duplicate runs where the stratum 
corneum remained intact throughout the course of the ex-
periment. Also the total amount of drug penetrating at 
the end of the 14-day period was between 50 and 80% of the 
applied dose. The penetration profile for experiments 
with broken stratum corneum did not register a steady-
state region but instead a gradual increase in the amount 
penetrating per unit area per unit time. 
The results demonstrate that; 
(a) The intact stratum corneum is probably the main 
effective barrier for passage of methotrexate 
through excised cadaver skin. 
TABLE V 
Relative Distribution of Methotrexate 14 Days After Application 
b Anlount· Washings of a .Penetrated Epidermis Applied Dose Recovered Accountabilit~ Set Run 
% % Epidermis % Dermis % 
I 1 23.79 49.22 13.88' 11.56 98.45 
II 2 41.75 48.47 2. 77 1.87 94.86 
3 33.56 54.27 3.45 1. 76 93.04 
III 4 14.34 62.85 1.65 2.16 81.00 
5 5.43 84.88 2.18 0.88 93.37 
IV 6 45.72 44.58 1.03 2~26 93.59 
7 34.80 52.10. 1.02 2.53 ·90.45 
aSet numbers refer to skin specimens from different donors. 






(b) The diffusion of methotrexate through the stratum 
corneum is·probably the rate-limiting step and not 
the telease of the drug from 50% propylene glycol 
in water. Alternatively, the values for distri-
bution of methotrexate at the end of the 14-day 
period could reflect relative solubilities rather 
than permeability differences. In view of the poor 
as suggested by the low partitioning value, the 
transfer of drug from propylene glycol-water phase 
to the stratum corneum may be the slow-step, re-
sulting in the retainment of the drug in the donor 
vehicle. 
(c) The water-bearing tissues of dermis appear to offer 
the least resistance to the passage of methotrexate. 
At present there appears to be no definitive explana-
tion available for the wide variation in observed results. 
Biological variation, tissue health, bacterial action, the 
presence of drugs .or their metabolites could.all influence 
the uptake of pteridines in the skin. 
Studies hitherto on percutaneous penetration of 
methotrexate (14, 18) as well as sodium salt of methotrex-
ate (22) have been carried out for comparatively shorter 
periods of time, not exceeding 20 hours. On the other 
hand, the present investigation was conducted over 14 days·. 
The results of the present work, especially the very high 
54 
lag times, clearly demonstrate the inability of methotrex-
ate to reach steady~state levels over short periods of 
time. The penetration rates calculated for data generated 
from experimental runs over short time interval could lead 
~ne to erroneous conclusions. In fact, the rates thus cal-
culated would be apparent steady state rates and reflect 
the slope of the 'non~linear' portion of the present 
pe~~trati9~ profile. 
The high values of lag time indicate the very low 
amounts of drug penetrating during the initial few hours. 
If this is the case, lack of percutaneous penetration 
during the period o.f application could be the reason for 
clinical ineffectiveness of topically applied methotrexate. 
EXPERIMENTAL III 
Effect of pH on Solubility and 
In Vitro Percutaneous Penetration 
The solubility of methotrexate in a series of 50% vjv 
aqueous propylene glycol over a pH range of 1 to 12 was 
determined and in vitro penetration of methotrexate from 
selected vehicles in the above series was examined. The 
results of these experiments were expected to provide 
meaningful information about the correlation, if any, of 
solubility and concentration of the dissolved unionized 
species with the rate of percutaneous penetration. The 
pH-rate of penetration profile was expected to give a 
greater insight into the pH dependency of the skin pene-
tration behavior of methotrexate. 
Solubility Studies 
Aqueous media in the pH range 1 to 12 were prepared 
(A d . I) . t . . d17 hl t . . dlS ppen 1x us1ng ace 1c ac1 , c oroace 1c ac1 , 
hydrochloric acid19 , and potassium hydroxide. 20 The pH 
17J.T.Baker Chemical Co., Phillipsburg NJ. 
18Eastman Organic Chemicals, Rochester NY. 
19 Matheson, Coleman and Bell, Norwood OH. 
20Mallinckrodt, Inc., St. Louis MO. 
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21 values of the aqueous media were checked on a· pH meter 
56 
equipped with a glass electrode and AgfAgCl internal refer-
ence electrode. Equal volumes of propylene glycol and the 
various aqueous solutions were then mixed to give 50% vfv 
propylene glycol in aqueous medium. Saturated solutions of 
methotrexate were prepared in each of the above mixtures. 
Solubility studies were conducted in a constant temperature 
. :room _at 22° + Q. 5°. The high-performance liquid chroma-
tography procedure adopted for analysis .of samples was the 
same as discussed in the preceding sections. 
Results and Discussion 
The solubility of methotrexate U.S.P. in the various 
50% vfv propylene glycol in aqueous media is shown in Table 
VI, Figure 17 ... In the table is also listed the pH of the 
aqueous solutions, the apparent pH of 50% vjvpropylene 
glycol-aqueous medium, and also the apparent pH of saturated 
solution of methotrexate in the various mixtures. A semi-
log plot of solubility against pH showed.a V-shaped curve 
with minimum solubility occurring around pH 4 (Figure 18). 
The higher solubility values of methotrexate in propylene 
glycol-acetic acid mixtures and propylene glycol-chloroacetic 
acid mixtures probably suggest some form of interaction of 
the drug with the respective aqueous .medium. Hence for 
21corning Model 125 pH Meter, VWR Scientific Inc., 
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Figure 17. Plot of solubility of methotrexate U.S.P. 
against pH of saturated solution of the drug 
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Figure 18. Semi-log plot of solubility of methotrexate U.S.P. 
against pH of saturated soluti6n of the drug 
in 50% vfv propylene glycol-aqueous medium. 
TABLE VI 
Solubility and pH of Methotrexate U.S.P. in 50% v/v Propylene Glycol :in Aqueous Medium 
pH Solubility 
Aqueous 50% v/v PG Satd. Soll1l! of 22° + 0.5° 
Aqueous Medium Medium in Aqueous MTX in 50%: v /v mg/ml Medium.· PG-Aqueous Med. 
0.001 M Potassium Hydroxide 11.02 10.62 4.33 0.6536 
0.01 M Potassium Hydroxide 12.12 11.78 5.29 1.4776 
0.02 M Potassium Hydroxide 12.18 12.06 5.84 2.4188 
0.05 M Potassium Hydroxide 12.56 12.48 6.34 4.9636 
0.001 M Acetic Acid 3.94 4.47 4.17 0.6329 
0.01 M Acetic Acid 3.39 3.80 4.00 0.5911 
0.001 M Chloroacetic Acid 3.14 3.50 3.90 0.5912 
0.01 M Chloroacetic Acid 2.50 2.85 3.19 0. 9713 
0.001 M Hydrochloric Acid 3.02 3.22 3.87 0.4633 
0.005 M Hydrochloric Acid 2.36 2.53 2.98 0.8976 
0.01 M Hydrochloric Acid 2.14 2.31 2.56 1.1211 




I I Jll. 
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in vitro. penetration studies these delivery systems were 
not employed. 
In propylene glycol-hydrochloric .acid mixtures, the 
solubility of methotrexate increased as the molar concen-
tration of hydrochloric acid in the vehicle mixture was 
increased. A semi-log. plot of molar concentration of 
hydrochloric acid against· molar solubility of methotrexate 
_ga.v§l a lj_near_ relationship with a correlation coefficient 
of 0.999 (Figure 19). From this plot, the solubility of 
methotrexate U.S.P. in 50% vfv propylene glycol-hydrochloric 
~:-
acid system.was found to be rel;ated to .the molar.concen-
tration of hydrochloric acid in the vehicle mixture by the 
equation; 
In (M of HCl) = 1626 x (Molar solubility of MTX) ..,. 8.5571 
In the propylene glycol-potassium hydroxide solution 
system, the solubility of.the drug increased as the molar 
concentration of potassium hydroxide in the vehicle mixture-
was increased. A plot of molar·solubility of methotrexate 
U.S .P. against molar concentration·· of potassium hydroxide in 
the vehicle mixtur~ showed a linear relationship with a cor-
relation coefficient of 0.999 ·(Figure 20). From the plot, 
the molar solubility of methotrexate U.S.P. in 50%.v/v propy-
len~ glycol-potassium hydroxide in water system was found to 
be related to the molar .concentration·of potassium hydroxide 
in the vehicle mixture by the equation; 
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Figure 19. Semi-log plot of molar concentration of hydro~ 
chloric acid against molar solubility of 
methotrexate U.S.P. in 50% vjv propylene glycol-
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Plot of molar solubility of methotrexate U.S.P. against molar 
concentration of potassium hydroxide in 50% vfv propylene 
glycol-potassium hydroxide in water mixtures. 





Effect of pH on In Vitro Percutaneous:· Penetraticm 
If passive diffusion is the predominant mechanism for 
percutaneous penetrat.ion of methotrexate, the changes in 
vehicle pH would be expected to influence the in vitro per-
cutaneous penetration rate of ~ethotrexate through.excised 
human cadaver skin, since transport by passive mechanism is 
maximized when the drug is present in the unionized form. 
A set of five saturated solutions of methotrexate in 50% 
vjv propylene glycol-aqueous media having pH values of 1.98, 
2.98, 3.87, 5~29, and 6.34 were chosen for this study. A 
saturated solution of methotrexate in 50% vjv propylene 
glycol-water having a pH.value of 4.12 was used as control~ 
The procedure for in vitro skin penetration studies was 
similar to the one discussed in the preceding section. One 
ml of the respective solution was used as donor vehicle. 
By using a saturated·solution,·the thermodynamic activity 
of the drug was mainted at the maximum·in each case. The 
penetration eXperiments were carried.out for approximately 
360 hours with minimal exposure to light because of the 
known photodecomposition·of methotrexate. During the actual 
run, the cells were covered ~ith Saran Wrap to insure occlu-
sion. Samples were withdrawn .once every 24 hours except for 
the initial 80 to 100 hours during which no sampling was 
undertaken. At the completion of the penetration experi~ 
ments, the donor vehicle rem~ning on the epidermal· side 
was recovered. The stratum corneum was separated from the 
64 
dermis and methotrexate from both th~se phases was extracted 
into the respective vehicle. Samples were analyzed by high-
performance liquid chromatography. New standard curves 
were prepared and used for each set of skin penetration 
studies. 
Resul.ts and Discussion 
Consi<ierab!e biologic variation exists among different 
skin specimens with regard to percutaneous absorption .. The 
effect of this variable was minimized by utilizing skin 
pieces from the same regional site for· each experiment. . In 
all, three sets of penetration experiments were carried out. 
In each set, six skin cells were run- one for each pH. 
This limitation was· dictated by the size.of the skin samples 
available from the same site. The penetration data for 
saturated solutions of methotrexate in 50% vjv propylene 
glycol in aqueous media were analyzed by plo~ting Q (the 
amount:penetrated per unit area) against time. Based upon 
this plot a regression analysis of the steady state region 
. . 
of the penetration curve was carried out and the rate and 
lag times were determined. 
The penetration profiles. for the three sets of experi-
ments are shown in Figures 21, 22., 23. The penetration data 
obtained from the Q versus t plots for the three sets of 
experiments are listed inTables VII, VIII and IX. The 
relative distribution and mass balance analysis of metho-
trexate at the end of 14 days were carried out for each set. 
30L 
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Figure 21. Effect of pH on in vitro percutaneous penetration of methotrexate: 
Q versus t plot, SET I. 
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Figure 22. Effect of pH on in vitro percutaneous penetration of methotrexate: 
Q versus t plot,-sET II. 
-1 NOTE: For pH 5.29 and 6.34 the data plotted is ~~ x 10 versus t. 
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Figure 23. Effect of pH on in vitro percutaneous penetration of methotrexate: 
Q versus t plot, SET III. 
NOTE: For pH 5. 29 and 6. 34 the data plotted is <~ x 10-l versus t. 





Effect of pH on.In Vitro Percutaneous Penetration.of Methotrexate 
Penetration Data : SET I 
pH Concentration 
Steady-State a 
Penetration Rate Lag Time Correlation Coefficientb 
lJ.g/ml. -2 -1 Hours· 11g em hr r 
1. 98 1405.9 0.0562 177 0.993 
2.98 897.6 0.0423 172 0.992 
3.87 463.3 0.4176 99 0.999 
4.12 566.5 0.2190 187 0.998 
5.29 1476.6 1.6150 226 0.998 
6.34 4963.6 1.8214 231 0.994 
aAll steady~state values were computed from the regression line drawn from. the data for 
each run.at each pH by using a TI-55 calculator. 















1.98 1405.9 0.2182 
2.98 897.6 0.3814 86 
3.87 463.3 o. 2721 125 
4.12 627.1 0.3692 
5.29 1477.6 1.1174 63 
6.34 4~63.6 3.1809 71 
a All steady-state values were computed from the regression line drawn fron1 the data 
for each run at each pH by using a TI-55 calculator. 






















































aAll steady-state values were computed from the regression line drawn fron1 the data for 
each run at each pH by usinga TI-55 calculator. 
b Reported r values are for steady-state region of the penetration data. 




The resul.ts are summarized- in Tables X, XI, and XII. 
Interpretation of Penetration Data 
At low pH, between 1 and .3, the amount of methotrexate 
retained by the stratum corneum was quite high. This may 
be because, at low pH, methotrexate is apparently capable 
of ionizing further as a weak base, L e. the ni trogens at 
positions 1 and 5 of the pteridine nucleus. and also _at 
---- positTon -10 assume a positive charge (Figure 1). This con-
tribution of protonation of nitrogen in retarding penetra-
tion is consistent with the data for penetration rate_and 
also the absolute amount penetrating at the end. of .14 days. 
In spite of the higher concentration of drug in the donor 
vehicle at this pH range, the rate of penetration was 
slower when compared to the 3-5 pH range and lesser amounts 
penetrated at the end of 14 days. Thus protonation of 
nitrogens i:r;t the methotrexate molecule appears to hinder 
penetration by passive diffusion as well as through trans-
follicular route, strongly suggesting surface interaction 
-with the stratum·corneum. 
In two out of the three sets of experiments carried 
out, the lag time at pH. 3. 87 was ·lower than at other pH 
values. The -shorter lag time, indicative of the ease of 
penetration is most likely due to the higher fraction of 
unionized.species present in the donor vehicle at.pH 3.87 
facilitating drug penetration by passive diffusion. Marked 
increase in the rate was seen when the pH of.the donor 
TABLE X 
I 
Effect of pH on RelativeDistribution of Methotrexate.l4 Days After Application 
SET I 
Applied Washings of 
pH Concentration Amount Penetrated EEidermis· AEElied Dose Recovered 
l.lg/ml % Absolute % Epidermis .. .% Dermis 
m 
1.98 1405.9 1.63 0.0230 94.08 0.16 0.63 
2.98 897.6 1. 75 0.0157 84.36 9.04 1.33 
3.87 463.3 45.01 0.2085 ;53. 65 1. 70 3.37 
4.12 566.5 14.34 0.0812 62.85 1.65 2.16 
5.29 1477.6 32~56 0.4808 48.47 4.04 4.69 



















Effect of pH on Relative Distribution of Methotrexate 14 Days AftE~r Application 
SET II 
Applied Washings of % 
Concentration Amount Penetrated EJ2idermis . AJ2J2lied Dos:e Recovered ~c:c~t.mt!bi:I_ity 
pg/ml % Absolute % % 
mg Epidermis Dermis 
1405.9 14.04 0.1973 32.50 25.90 5.44 75.92 
897.6 25.57 0.2300 55.64 ·1.24 2.63 85.08 
463.3 30.26 0.1402 67.26· 1.19 2.34 101.10 
627.1 45.72 0.2867 44.58 1.03 2.26 93.59 
1477.6 48.74 0.7202 47.80 0.69 4.53 101.77 











Effect of pH on Relative Distribution of Methotrexate 14 Days After Application 
SET III 
Applied Washings of % 
Concentration Amount Penetrated EJ2idermis AJ2plied Dose Recovered Accountability 
pg/ml % Absolute % % 
mg Epidermis Dermis 
1405.9 18.14 0.0255 21.85 38.69 3.60 82.28 
897.6 17.20 0.0154 61.66. 3.08 2.46 84.40 
463.3 65.56 0.3037 40.51 1.18 2.94 110.19 
627.1 34.80 0.2183 52.10 1.02 2.53 90.45 
1477.6 73.40 1.0845 18.85 0.75 4.30 97.30 





vehicle was raised from 2.98.to 3.87. In spite of the 
increase in concentration of the drug at pH 4.12, the rate 
was slightly lower than at pH 3.87. The high values of per-
cent amount penetrating in 14 days for the pH range 3 to 5, 
strongly suggests the major contribution towards penetra-
tion from passive diffusion.with comparatively minimal ef-
feet from transfollicular·and appendageal routes. 
Between pH 4.12 and pH 5.29, a sharp rise in. the pene-
tration rate was observed while beyond pH 5.29 the rate of 
penetration appeared to level off. The fraction of the 
unionized species in the donor vehicle would be expected 
to be very low beyond·· pH 5 .. Hence, the high val ties for 
penetration. rate above pH 5, consistent with the increased 
/ 
solubility of methotrexate, appear·to suggest. the increasing 
contribution of pore transport with increasing pH. 
While these data suggest considerable variation be-
tween different skin specimens towards percutaneous absorp-
t.ion of methotrexate and· in some cases variation even 
within the same skin specimens; a semi-log rate of pene-
tration-pH profile (Figure 24) for the three sets of experi-
ments revealed a definite trend. This·ismore convincingly 
demonstrated in a semi..,.log plot of the average value of 
the penetration rate for the three sets of experiments 
against pH (Figure 25). 
At the chosen·pH values, calculation of the fraction 
of methotrexate present as each species (Appendix II)--
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Figure 24. Semi-log plot of rate of penetration against 
pH for methotrexate absorption from saturated 
solutions o£ the drug in 50% vjv aqueous 
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Semi-log plot of average ratel of penetration against pH for 
methotrexate absorption from ~aturated solutions of the 4rug 







unionized, monoprotic, and aprotic revealed no defin.i te 
correlation.of·the rate of penetration with the fraction 
of any of the individual species. This· was true for each 
of the three different sets of pKa values reported in the 
literature for methotrexate. Of course it should be recog-
nized that in propylene glycol-aqueous media, the pK values a 
for methotrexate may be somewhat .different from the. hitherto 
reported literature values. 
These findings suggested that·at any given pH, the 
absorption of methotrexate from 50% vjv propylene glycol 
in aqueous medi urn· might. be dependent on the .combined effect 
of transport by passive diffusion.~nd transfollicular and 
appendagea1 routes. It is extremely difficult to delineate 
the individual.contribution.due to each of these factors. 
The salient features of the effect· of pH on in vitro per-
cutaneous penetration of methotrexate may be summarized 
as follows: 
(a) At low pH, between 1 and 3, protonation.of the 
nitrogens ~etards penetration; 
(b) Concentration of the unionized species is optimal 
between pH 3 and 4, facilitating penetration by 
passive ·diffusion, .but low solubility in this pH 
range limits transport; and 
(c) With increasing pH, contributions from passive 
diffusion decrease while contributions from pore 
transport increase. 
CONCLUDING REMARKS 
Effectiveness of systematically administered methotrex-
ate in psoriasis has prompted continuing effort towards 
therapy·by topical route. However, controversy reigns. over 
the clinical efficacy of this mode·of therapy. Several 
theories, most of which are neither documented nor denied 
by experimental· facts, have been proposed to explain the 
wide variation in clinical .response to topical treatment 
with methotrexate. 
A 'systemic site of action' has been cited as one of 
the possible reasons for unsuccessful results with topical 
therapy.. Van Scott and Reinertson ( 11) in 1959,. first sug-
gested that pharamcological action of methotrexate in 
psoriasis might require initiation at a distant systemic 
site. Nurse (9) in 1963, proposed that a depletion of 
body stores of folinic acid may·be necessary for metho-
trexate to act on psoriatic epidermal cells. Comaish (13) 
in 1969 hypothesized that methotrexate might act on skin 
cells indirectly by its effect on the liver. According 
toCipriano et al. (35), .inhibition. of hepatic production 
5 of N -methylt~trahydrofolate rather than inhibit~on of 
endogenous production of these compounds by the epidermal 
cells might be important. 
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Too rap~d dispersal .from the site of application fol-
lowing intralesional injection has been proposed for the 
ineffectiveness through this route as well (9). 
Inhibition of ~ritiated deoxyuridine incorporation in 
explants of human skin following local application of metho-
trexate as shown by Marks et al., (36) casts doubt on the 
theory that conversion. products of methotrexate may·be re-
--sponsib-le .for- the eff-ectiveness of systemically adminis-· 
tered methotrexate. 
Lack of percutaneous penetration.has often been con-
sidered as one of the possible reasons for the clinical in-
efficacy of topical methotrexate~ Comaish and Juhlin (12) 
reported the only quantiative. estimate of percutaneously 
absorbed methotrexate f'ollowing .in vivo studies. According 
to these authors, 0.06 to 0.5% of the total topically ap-
plied methotrexate.was recovered in the urine after 72 hours 
in four patients. 
Apart from the fact that stratum corneum forms the 
main effective barrier for penetration of topically applied 
methotrexate (as confirmed·by this study), there appears 
to be little or no consensus regarding mechanism of topical 
absorption of methotrexate. Unfortunately, research on 
topical methotrexate has not been methodical. Clinical 
trials have preceded adequate physicochemical and formula-
tion studies .leading to questionable predictions and 
postulations about the biochemical effects of methotrexate. 
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Impurities in the samples of methotrexate used and inade-
quate analytical techniques. have. further added to the con-
fusion. 
In the present work, two important physiochemical 
characteristics of methotrexate solubility and partition 
coefficient, have been .examined and. generated data have been 
utilized as an aid in the development of a delivery sys-
tem for methotrexate. The potential of 50% vjv aqueous 
propylene glycol as a vehicle for topical delivery of 
methotrexate was investigated. Examination of solubility 
of the drug in a propylene glycol-water system revealed 
a logarithmically increasing relationship between solu-
bility and percent propylene glycol. The partition coeffi-
cient of methotrexate when tested in an isopropyl myristate/ 
propylene glycoi-water system, was found to decreas'e with 
increasing concentrations of propylene glycol-in the vehicle 
mixture. 
The solubility and in vitro percutaneous penetration 
rates of methotrexate in 50% vjv propylene glycol-aqueous 
medium in the pH range 2 to 6 was also investigated. The 
solubility-pH profile showed a min.imum at approximately· 
pH 4. 
The results of the in vitro penetration studies showed 
that at low pH values, between 1 and 3, a high perce~tage 
of the total applied dose was retained in the stratum 
corneum. This may be due to the possible protonation of 
the nitrogens at positions 1 and 5 of the pteridine nucleus 
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and also at position 10~ leading to interaction with the 
stratum corneum. In the.pH range 3 to· 5, concentration 
of the unionized species was optimal. The high values 
for percent. penetrating at the end of 14 days and compara-
tively low values for lag time strongly suggested the major 
contribution towards penetration was from passive diffusion 
with minimal effects through transfollicular and trans-
appt3ndage_al routes. Beyond pH 5, the increase in penetra-
tion rate was attributed to the increase in concentration 
of methotrexate in the donor vehicle. The very high values 
for lag time beyond pH 5 were indicative of diminished con-
tribution of passive transport relative to other pathways 
such as intercellular and.transfollicular pathways. Inter-
estingly, increased solubility at pH 5.29 and 6.34 did not 
contribute to low lag times--underscoring the importance 
of contribution from passive diffusion .. The high lag times 
beyond pH 5 further raise the possibility of drug inter~ 
action with the skin. 
No definite correlation was apparent between the 
penetration rates at various pH and the total concentration 
of the drug in the vehicle. Calculation of the fraction 
of different species of methotrexate present at each pH 
based on the pK values reported iti"the literature showed 
a 
no correlation between the penetration rates and concen-
tration of any of the three individual species present. 
The penetration rate-pH profile for experimental runs 
was reproducible in spite of the wide variation between 
different skin specimens. 
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To provide.adequate release, a vehicle must dissolve 
the drug, but not to the extent that the drug remains pref-
erentially in the vehicle; the stratum corneumjvehicle 
partitioning must be adequate. The reults of this investi-
gation reveal the complicated penetration behavior of metho-
trexate, at least from the vehicle system examined. Further, 
the results suggest that lack of percutaneous penetration 
and limited duration of clinical trials might· as well have 
been the main reasons for·t.he reported clinical ineffec-
tiveness of topical methotrexate. 
It is suggested that the optimal conditions for 
topical delivery of methotrexate should include a vehicle 
system with a pH of about 4 to 6 capable of dissolving the 
drug. to the extent· of 0. 4% wjv or more while still retain-
ing good partitioning characteristics for the skin. It 
would be worthwhile examining the. in vitro skin penetra-
tion from such vehicle systems. The efforts along these 
lines might yet unlock the-clinical potential of metho-
trexate in topical treatment of psoriasis. 
APPENDIX I 
Preparation of Aqueous Media 
(A) Hydrochloric Acid Solutions: 
Concentrated hydrochloric acid (11.9 N) was used for 
dilution. 




1.250 ml of concentrated hydrochloric acid 
diluted to 500 ml with distilled water to 
give approximately 0.03M hydrochloric acid. 
0.420 ml of concentrated hydrochloric acid 
diluted to 500 ml with distilled water to 
give approximately O.OlM hydrochloric acid. 
0.208 ml.of concentrated hydrochloric acid 
diluted to 500 ml with distilled water to 
give approximately 0.005M hydrochloric acid. 
0.042 ml of concentrat~d.hydrochloric acid 
diluted to 500 ml with distilled water to 
give approximately 0.001M hydrochloric acid. 
(B) Potassium Hydroxide Solutions: 
pH 11.02 
pH 12.12 
0.056 g potassium hydroxide dissolved in 
1000 ml distilled water to give approximately 
O.OOlM potassium hydroxide in water. 
0.560 g potassium hydroxide dissolved in 
1000 ml distilled water to give approximately 





1.120 g potassium hydroxide dissolved in 
1000 ml dist~lled water to give approximately 
0.02M potassium hydroxide in water. 
2.80 g potassium hydroxide dissolved in 1000· ml 
distil.led water to give approximately 0.05M 
potassium hydroxide in water. 
(C) Acetic Acid Solutions: 
··- (}lacial ac~tic acid (17.4 N) was used for dilution. 
pH 3.39 0.575 ml of glacial acetic acid diluted to 
1000 ml with distilled water ·to give approxi-
mately O.OlM acetic acid. 
pH 3.94. 0.0575 ml of glacial acetic acid diluted to 
1000 ml with distilled water to give approxi-
mately 0. OOlM a.cetic acid. 
(D) Chloroacetic Acid Solutions: 
pH 2~50 0.945 g chloroacetic acid dissolved in 1000 
ml distilled water to give approximately 
O.OlM chloroacetic. acid in water. 
pH 3.14 0.0945 g chloroacetic acid dissolved in 1000 
ml distilled water to give approximately 
0.001M chloroacetic acid inwater. 
APPENDIX II 
Calculation of the Fraction of Unionized Methotrexate 
To calcu~ate the fraction of methotrexate present as 
each species - diprotic, unionized (a2 ), monoprotic (a1 ) 
_and_ aprotic (a
0
) the equilibria are (37): 




The mass balance on methotrexate is: 




where C is the analytical concentration of methotrexate. 
Since [H+] and C are known, there ar'e. a total of three 
equations in three unknowns. 
The fraction of unionized methotrexate present is 
the ratio of the concentration of the unionized species 
to the analytical concentration, 
[MTX] = c ( 4) 
The reciprocal of the fraction of unionized drug can be 




[MTX] = 1 (5) = 
c 
= 1 + + (6) 
Thus ct2' the fraction of unionized drug can be calculated 
--frem -its reciprocal using 1""\-'l'ln..f...; __ Ia\ +'h ...... ~"'-"'-+-"'~ ...,.v o;:;y_u.a.v..LVU 1.. v)' V.l.LC .L <:;; J:.IV .L u.<:;;U. J:.IU• .a 
values and the measured pH of the Solutions. 
The fraction of monoprotic methotrexate present is 
the ratio ofJ the concentration of the monoprotic. species 
to the analytical concentration, 
(7) 
The reciprocal of the·fraction of rnonoprotic species can 
be calculated by dividing each term of equation (3) by· 
[MTX-], thus; 
1 c lMTX] + 1 + lMTX=] = = 




1 1 + + 
a2 
= -K- 7 ct1 al 
(9) 
Thus a 1 , the fraction of monoprotic drug can be calculated 
from its reciprocal using equation (9), the reported pKa 
values and the measured pH of the solution. 
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